Frontiers in Cardiovascular Medicine

FEBRUARY 5, 2025

Small aortic annulus poses a major challenge in aortic valve replacement due to the increased risk of prosthesispatient mismatch (PPM) and increased surgical risk. In recent years, transcatheter aortic valve replacement (TAVR) has emerged as a popular alternative to the traditional surgical aortic valve replacement.

Aortic valve 52

Aortic valve Aortic TAVR Myocardial Infarction 52

Open Heart

APRIL 27, 2023

Background and aims Randomised controlled trials comparing transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR) were performed in highly selected populations and data regarding long-term secondary complications beyond mortality are scarce. All-cause mortality at 1 year (HR 1.21; 95% CI 1.02

Aortic valve 52

Aortic valve TAVR Aortic Outcomes 52

Journal of Cardiovascular Pharmacology

NOVEMBER 21, 2023

Abstract: Transcatheter aortic valve replacement (TAVR) is an interventional procedure performed in patients with severe aortic stenosis and often required perioperative antiplatelet therapy. Most previous studies have focused on antiplatelet therapy following TAVR.

Aortic valve 40

Aortic valve Aortic TAVR Myocardial Infarction 40

DAIC

FEBRUARY 29, 2024

24: Joint American College of Cardiology/Journal of the American College of Cardiology Late-Breaking Clinical Trials (Session 402) Saturday, April 6 9:30 – 10:30 a.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

Open Heart

JANUARY 19, 2023

Objective Postprocedural ischaemic and bleeding risks after transcatheter aortic valve replacement (TAVR) remain a major concern. We aimed to assess the accuracy of percutaneous coronary intervention (PCI)-derived models and the performance of a recalibrated model that included variables more applicable to TAVR.

Aortic valve 52

Aortic valve TAVR Aortic Myocardial Infarction 52

Journal of the American Heart Association

MARCH 21, 2025

BackgroundCurrent guidelines and expert consensus recommend lifelong single antiplatelet therapy for patients undergoing transcatheter aortic valve replacement who have no indication for anticoagulation or dual antiplatelet therapy. Journal of the American Heart Association, Ahead of Print.

Aortic valve 40

Aortic valve Aortic Myocardial Infarction TAVR 40

Circulation: Cardiovascular Interventions

OCTOBER 22, 2023

Background:Atherosclerotic cardiovascular disease (ASCVD) is highly prevalent in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement (TAVR). Exposure of interest was PVD. Primary outcome was all-cause mortality.

Aortic valve 40

Aortic valve Aortic TAVR Outcomes 40